Lialda is manufactured by Shire USA, Inc.
Lialda belongs to a group of medications called aminosalicylates. It is thought that the medication works by inhibiting the production of inflammatory chemicals in the lining of the
colon. Lialda decreases the production of prostaglandins and leukotrienes, chemicals that lead to the inflammation caused by ulcerative colitis.
The tablets have a special delayed-release coating. This coating prevents the tablets from dissolving until they reach the colon.
Studies have looked at using Lialda to treat active cases of mild to moderate ulcerative colitis. In one study, up to 41.2 percent of people taking the drug experienced ulcerative colitis remission within eight weeks, compared to just 22.1 percent of those not taking it. In this study, ulcerative colitis remission was defined as: